Akums Drugs And Pharmaceuticals Peer Comparison

NSE: AKUMS | BSE: 544222

₹821.45

₹37.75 (4.82%)

As on 21-Sep-2026IST

Market cap

₹12,926 Cr

Revenue (TTM)

₹4,502 Cr

P/E Ratio

44.3

P/B Ratio

3.8

Div. Yield

0.4 %

Edit

	Akums Drugs And Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	12,926	35,548	28,659	28,019	28,577
Revenue (₹ Cr)	4,502	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	292.69	414.00	288.22	387.35	-371.81
Net Margin (%)	6.32	11.23	14.79	26.01	-3.93
RoE (%)	9.44	8.38	29.77	25.18	-3.85
Price to Earnings	44.31	86.91	99.43	72.55	--
Price-To-Book	3.78	7.06	21.35	16.24	3.57

Income Statement (₹ Cr)

	Akums Drugs And Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	4,501.61	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	4,633.99	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	3,933.88	2,792.00	1,485.56	919.25	8,195.15
EBITDA	567.73	772.00	450.24	542.56	1,010.13
Depreciation	158.70	226.00	50.83	37.68	857.51
EBIT	409.04	546.00	399.41	504.88	152.62
Interest	95.69	217.00	40.84	3.77	342.73
Other Income	132.37	122.00	12.78	27.45	244.31
Exceptional Items	-20.02	12.00	0.00	0.00	-216.88
Profit before Tax	425.69	463.00	371.35	528.56	-162.68
Provision for Tax	133.00	49.00	83.14	141.21	209.13
Profit after Tax	292.69	414.00	288.22	387.35	-371.81

	Akums Drugs And Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	3,313.35	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	-0.97	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	1,021.09	1,712.00	202.03	42.40	5,044.14
Current Liabilities	1,094.76	1,622.00	835.87	230.82	4,758.28
Total Liabilities	5,429.26	8,578.00	2,326.71	1,983.96	17,723.32

	Akums Drugs And Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	1,635.38	5,343.00	519.60	1,026.85	10,211.52
Current Assets	3,559.86	2,606.00	1,681.81	881.27	7,191.66
Total Assets	5,429.26	8,578.00	2,326.71	1,983.96	17,723.32
Total Debt*	72.95	2,125.00	259.37	26.49	5,495.48
Net Current Assets	2,465.10	984.00	845.94	650.46	2,433.38
Contingent Liabilities	99.40	768.26	19.09	17.25	95.72

	Akums Drugs And Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	1,181.20	390.00	205.05	292.17	1,652.60
Cash Flow from Investing Activities	-930.27	-241.00	-409.72	-265.94	-826.03
Cash from Financing Activities	33.88	-54.00	283.07	4.10	-38.98
Net Cash Inflow / Outflow	284.81	95.00	78.39	30.33	787.59

	Akums Drugs And Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	14.77	6.79	29.22	32.42	1.24
ROE (%)	9.44	8.38	29.77	25.18	-3.85
ROA (%)	6.12	4.94	24.77	21.93	-2.21
EBIT Margin (%)	9.09	15.32	20.63	34.54	1.66
Net Margin (%)	6.32	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Akums Drugs And Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	9.18	18.37	46.65	40.90	0.78
EBIT Growth (%)	32.32	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	-15.71	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	-4.44	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	8.74	13.47	144.31	26.03	0.33

	Akums Drugs And Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	42.36	89.21	97.91	72.55	-91.33
Price / Book Value	3.78	7.06	21.35	16.24	3.57
Dividend Yield (%)	0.37	0.00	0.09	0.07	0.00
EV/EBITDA	19.94	47.94	63.46	51.28	32.39
Market Cap (₹ Cr)	7,135.27	19,071.62	12,753.19	20,944.75	18,108.89

	Akums Drugs And Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.00	0.31	0.11	0.02	0.53
Short term debt to equity ratio	0.02	0.09	0.05	0.02	0.09
Current Ratio	3.25	1.61	2.01	3.82	1.51
Quick Ratio	2.56	1.06	1.14	2.82	0.87
Interest Coverage	5.45	3.13	10.09	141.16	0.53

	Akums Drugs And Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	17.70	16.50	26.28	24.80	23.44
Asset Turnover	0.94	0.43	1.66	0.83	0.55
Receivable days	65.60	58.75	40.13	88.98	78.20
Inventory Days	60.15	75.82	60.29	56.04	93.30
Payable days	90.39	186.21	232.47	99.95	226.14
Cash Conversion Cycle	35.36	-51.64	-132.04	45.07	-54.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.